SEC 8-K filings with transcript text
Oct 19, 2026
2 ex99-1.htm
Exhibit 99.1
Continued Arbli™ sales growth, combined with REZENOPY™ commercial launch in August 2026
and initial wholesale shipments, drives significant sequential revenue growth
Arbli™ wholesale unit sales increased 74% sequentially, with recent institutional formulary
additions supporting continued commercial expansion
NY, Oct. 13, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced preliminary, unaudited revenue of approximately $1.22 million for the third quarter ended September 30, 2026, representing an increase of 256% compared to approximately $344,000 in the second quarter of 2026.
The substantial sequential increase in preliminary revenue reflects the successful commercial launch of REZENOPY™ and initial wholesale shipments, as well as continued sales growth and increasing market adoption of Arbli™. These results mark an important milestone in Scienture’s commercial expansion, reflecting the addition of a second FDA-approved product and continued progress toward building a diversified, multi-product pharmaceutical portfolio.
“These preliminary third-quarter revenue results mark a significant inflection point for Scienture, demonstrating the accelerating commercial momentum of our expanding pharmaceutical portfolio,” said Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings. “With Arbli™ continuing to gain traction and REZENOPY™ becoming our second commercial-stage product following its August 2026 launch, we believe Scienture is well-positioned to meaningfully accelerate top-line revenue growth through the remainder of 2026 and into 2027. As we work to expand our distribution channels and drive commercial adoption, we believe our historically high gross margins will provide significant operating leverage, supporting our goal of achieving profitability in 2027.”
“Our preliminary third-quarter revenues reflect the progress we have made in executing our commercial strategy and establishing Scienture as a growing specialty pharmaceutical company,” said Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture Holdings. “Looking ahead, we see significant opportunities to further penetrate our addressable markets, particularly as we focus on increasing institutional adoption, expanding healthcare provider engagement and entering strategic commercial partnerships. With two differentiated FDA-approved products addressing important unmet needs commercialized, we believe Scienture is well-positioned to build a sustainable, high-value pharmaceutical business and deliver long-term value to shareholders.”
The preliminary revenue figures described in this press release are unaudited and subject to customary adjustments. The Company’s full financial results for Q3 2026 will be included in a Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission in accordance with federal securities rules and regulations.
About Arbli™
Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.
Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:
●Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
●Reduction of the risk of strok
Aug 20, 2026
2 ex99-1.htm
Exhibit 99.1
Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company’s Growing Commercial Revenue Base
Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million
Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million
Commenced Commercial Launch of REZENOPY™, Establishing the Company’s Second Commercial Product and Expanding Its Revenue-Generating Portfolio
NY, Aug. 14, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three and six months ended June 30, 2026.
Second Quarter 2026 and First Half 2026 Financial Highlights
● Revenue increased approximately 510% sequentially to $343,639 in Q2 2026, compared with $56,325 in Q1 2026.
● First-half 2026 revenue increased significantly year-over-year to $399,964, compared with $10,258 for the first six months of 2025.
● Q2 2026 gross profit was $335,779, compared to $0 in Q2 2025, with Q2 2026 gross margin being approximately 97.7%.
● First-half 2026 gross profit increased to $389,629, compared with $673 for the first six months of 2025, with a gross margin of approximately 97.4% for the first half of 2026.
● Q2 2026 operating expenses decreased approximately 41% year-over-year to approximately $3.0 million, compared with approximately $5.2 million in Q2 2025, demonstrating continued expense management and operating discipline.
● First-half 2026 operating expenses decreased approximately 24% to about $6.6 million, compared with approximately $8.7 million during the first six months of 2025.
● Q2 2026 operating loss improved approximately 48% to about $2.7 million, compared with an operating loss of approximately $5.2 million in Q2 2025.
● Q2 2026 net loss narrowed approximately 58% to about $2.8 million, compared with a net loss of approximately $6.7 million in Q2 2025. Basic and diluted net loss per share improved to $0.07 from $0.48 during that time.
● First-half 2026 net loss narrowed approximately 36% to about $6.2 million, compared with approximately $9.8 million for the first six months of 2025. Basic and diluted net loss per share improved to $0.16 from $0.83 during that time.
● As of June 30, 2026, the Company had cash, cash equivalents and restricted cash of approximately $11.2 million compared to approximately $6.7 million of cash and cash equivalents as of December 31, 2025.
Key Operational Highlights in Q2 2026 and Subsequent Events:
● United States Patent and Trademark Office (USPTO) granted a second patent covering REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg, strengthening intellectual property protection for the product through 2041.
● United States Patent and Trademark Office (USPTO) granted a third patent covering Arbli™ (losartan potassium) oral suspension, further strengthening the product’s intellectual property portfolio and extending expected market exclusivity through 2041.
● Secured formulary coverage for REZENOPY™ with a large national health plan and expanded the commercial team to support market penetration and growth.
● Expanded ARBLI™ payer coverage and commercial access, adding approximately 12.5 million covered lives.
● Commenced the commercial launch of REZENOPY™ and began fulfillment of initial purchase orders, marking an important milestone in the Company’s commercialization strategy.
Narasimhan Mani, President, Interim CFO, and Co-CEO of Scienture, commented, “We believe our second-quarter results demonstrate that Scienture has reached an important inflection point. Revenue for Q2 20226 increased about 510% sequentially, from approximately $56,000 in the first quarter to approximately $344,000 in the second quarter. At the same time, we generated gross margins of approximately 98%, reduced operating expenses by about 41% year-over-year and narrowed our net loss by approximately 58%. We also ended the quarter with approximately $11.2 million in cash, cash equivalents and restricted cash, compared with about $6.7 million at year-end 2025, providing us with a stronger financial position as we execute the next phase of our commercial growth strategy. We believe these results demonstrate that we are on the right path to deliver value added business growth in the coming quarters and that we are beginning to realize the operating leverage we have been working toward.”
“Arbli’s continued commercial progress gives us confidence in our ability to build and scale differentia
May 22, 2026
2 ex99-1.htm
Exhibit 99.1
Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
NY, May 18, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three months ended March 31, 2026.
Q1 2026 Financial Highlights Compared to Q1 2025:
● Revenue increased to approximately $56 thousand for the three months ended March 31, 2026, compared to approximately $10 thousand in the prior-year three-month period, representing an increase of approximately 449% year-over-year, reflecting incremental product orders for ArbliTM in addition to the initial launch quantities ordered in the fourth quarter of 2025
● Gross profit increased substantially to approximately $54 thousand, compared to approximately $673 in the prior-year three-month period, representing an increase of approximately 7900% year-over-year, primarily as a result of the increase in ArbliTM product orders
● Gross margin expanded to approximately 95.6% for the three months ended March 31, 2026, compared to approximately 6.6% in the prior-year three-month period, also as a result of the increase in ArbliTM product orders
Key Operational Highlights in Q1 2026 and Subsequent Events:
● United States Patent and Trademark Office (USPTO) granted a third patent covering ArbliTM (losartan potassium) oral suspension, further strengthening the product’s intellectual property portfolio and extending expected market exclusivity through 2041
● Received an Orange Book-listable patent for REZENOPYTM (naloxone HCl) nasal spray 10 mg, the highest-dose FDA-approved naloxone HCl nasal spray for emergency opioid overdose treatment
● Formalized multiple commercial GPO agreements for REZENOPYTM, expanding access to over 5,000 healthcare institutions and reaching approximately 60% of the U.S. institutional market, including first responders, EMS providers, and rehabilitation centers
● Secured $11.0 Million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of R&D pipeline
Narasimhan Mani, President and Co-CEO of Scienture, commented, “Our financial results for the quarter reflect the early progress of our commercialization strategy, with revenue increasing approximately 449% year-over-year to $56 thousand, gross profit increasing approximately 7900% year-over-year to $54 thousand, and gross margin expanding significantly to approximately 95.6%, compared to 6.6% in the prior-year period. The increase in revenue and gross margin reflects incremental product orders received for ArbliTM during the first quarter of 2026, following the significant initial launch quantity orders recorded in the fourth quarter of 2025.”
“During the quarter, we experienced continued month-over-month growth in both prescriptions and units sold for ArbliTM. We are actively working to enhance our promotional and commercial activities around the product to further increase physician awareness and market penetration. We also continue to advance key commercial initiatives to support the planned launch of REZENOPYTM. Our sales force is scheduled to begin operations on June 1, 2026, targeting key accounts and purchasing organizations, and we have also successfully secured key GPO contracts that we believe will support broad commercial access and accelerate adoption following launch. Together, we believe the continued commercialization of ArbliTM and the anticipated launch of REZENOPYTM will have a meaningful impact on our business performance during the second half of 2026,” added Mani.
“In addition, we recently secured $11.0 million through a non-dilutive debt financing transaction that we believe significantly strengthens our capital position and provides important financial flexibility as we continue scaling our commercial operations,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “We believe this financing will serve as a catalyst to help position the Company toward anticipated profitability in 2027, while also supporting the continued growth of our commercial product portfolio and the progression of our R&D pipeline.”
Q1 2026 Financial Summary
Revenue for the year three months ended March 31, 2026 increased 449% to $56 thousand, compared to $10 thousand in the prior year period, driven by the continued ramp of wholesale distribution sales of SCN-102 (ArbliTM) following its commercial launch. Gross profit increased to approximately $54 thousand, compared to approximately $673 in the prior-year period, representing year-over-year growth of approximatel
This page provides Scienture Holdings Inc. (SCNX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on SCNX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.